Palliative radiation therapy for head and neck cancer: Toward an optimal fractionation scheme
- 16 September 2008
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 30 (12), 1586-1591
- https://doi.org/10.1002/hed.20894
Abstract
Background. To analyze the efficacy of various fractionation schedules for the palliation of head and neck cancer with radiation therapy. Methods. Sixty patients completed palliative irradiation to primary head and neck sites. The most commonly used fractionation regimen was the one previously described by the Radiation Therapy Oncology Group (RTOG) protocol 85‐02 and was designed to deliver 440 cGy using 370 cGy fractionation, administered twice a day for 2 consecutive days at 2‐ to 3‐week intervals for 3 total cycles. Results. The rates of palliative response were 83%, 77%, 67%, 86%, and 60% among those treated using the RTOG regimen, 7000 cGy/35 fractions, 3000 cGy/10 fractions, 3750 cGy/15 fractions, and 2000 cGy/5 fractions, respectively (p = .42). Nine percent (2/23) of those treated with the RTOG regimen developed grade 3+ toxicity compared with 37% among those treated with other schedules (p = .01). Conclusion. Although all of the analyzed schedules were effective at providing palliation, the RTOG 85‐02 regimen was associated with less toxicity. © 2008 Wiley Periodicals, Inc. Head Neck, 2008Keywords
This publication has 20 references indexed in Scilit:
- A phase II evaluation of a 3‐hour infusion of paclitaxel, cisplatin, and 5‐fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neckCancer, 2006
- Risk Factors for Distant Metastases in Head and Neck Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2006
- Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 2005
- Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinomaCancer, 2001
- A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003International Journal of Radiation Oncology*Biology*Physics, 2000
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology*Biology*Physics, 1995
- Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapyRadiotherapy and Oncology, 1992
- Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: Preliminary report of RTOG 8502International Journal of Radiation Oncology*Biology*Physics, 1989
- Short course high fractional dose irradiation in advanced and recurrent head and neck cancerInternational Journal of Radiation Oncology*Biology*Physics, 1979
- Whole pelvis megavoltage irradiation with single doses of 1000 rad to palliate advanced gynecologic cancersInternational Journal of Radiation Oncology*Biology*Physics, 1979